CSF2 and melanoma: In 2015, a new drug for oncolytic virotherapy, talimogene laherparepvec (IMLYGIC), a herpes simplex virus, that has been genetically engineered to express granulocyte macrophage colony stimulating factor (GM-CSF) to treat advanced melanoma was first approved by the Food and Drug Administration (FDA), and was licensed for marketing by the European Commission.